Transcatheter Tricuspid Valve Intervention: Coaptation Devices

Muntané‐Carol, Guillem; Alperi, Alberto; Faroux, Laurent; Bédard, Élisabeth; Philippon, François; Rodés‐Cabau, Josep

doi:10.3389/fcvm.2020.00139

Cited by 31 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preprocedural transthoracic and transoesophageal echocardiography were performed in all patients for assessing TR severity and suitability for edge-to-edge device implantation. Patients were treated predominantly with the Triclip system [7] but Mitraclip was also used in a compassionate and/or off-label use [8]. Details regarding the TTVr procedure and special features of the edge-to-edge device have been published elsewhere [9].…”

Section: Patient Selection and Follow-upmentioning

confidence: 99%

Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program

Cepas-Guillén

Mancera

Bofarull

et al. 2021

JCM

View full text Add to dashboard Cite

Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution. Methods: We included consecutive patients who underwent edge-to-edge TTVr systems. The primary efficacy endpoint was a reduction in the TR of at least one grade. The primary safety endpoint was procedure-related clinical serious adverse events. Results: A total of 28 patients underwent TTVr with edge-to-edge systems. All patients presented with at least severe TR with a high impact on quality of life (82% of patients in NYHA class ≥ III). The Triclip system was the most used device (89%). The primary efficacy endpoint was met in all patients. Only one patient experienced a procedural complication (femoral pseudoaneurysm). At three-month follow-up, 83% of patients were in NYHA I or II (18% baseline vs. 83% 3 months follow-up; p < 0.001). Echocardiography follow-up showed residual TR ≤ 2 in 79% of patients (paired p < 0.001). At the maximum follow-up (median follow up = 372 days), no patients had died. Conclusions: Edge-to-edge TTVr systems seem to represent a very valid alternative to prevent morbidity and mortality associated with TR as depicted by the favorable efficacy and safety.

show abstract

Section: Patient Selection and Follow-upmentioning

confidence: 99%

Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program

Cepas-Guillén

Mancera

Bofarull

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…The FORMA system (Edwards Lifesciences, Irvine, CA, USA) is designed to increase leaflet coaptation, occupying the regurgitant orifice with a spacer [39]. A guide is advanced through the subclavian or axillary vein and anchored in the apex of the right ventricle.…”

Section: Percutaneous Coaptation Devicesmentioning

confidence: 99%

Percutaneous Treatment of Tricuspid Regurgitation

Minguito‐Carazo¹,

Benito‐González²,

Estévez‐Loureiro³

et al. 2021

Interventional Treatment for Structural Heart Disease

View full text Add to dashboard Cite

Tricuspid valve regurgitation is one of the most common valvular disorders and moderate to severe tricuspid regurgitation is consistently associated to an increased morbidity and mortality. From an etiopathological perspective, tricuspid regurgitation can be classified in primary, due to the organic disease of any of the valve components, or secondary, as a result of tricuspid valve annulus dilatation, adverse right ventricular remodeling and tricuspid valve leaflet tethering. Despite its poor prognosis, most patients with tricuspid insufficiency are managed conservatively and only those with concomitant left heart valvular disease do finally go surgery in the real-world setting. In fact, outcomes of conventional surgery in patients with isolated tricuspid regurgitation are poor and this approach has not proven yet any survival benefit over stand-alone medical therapy. Given this unmet need, new transcatheter techniques have been developed in the last years, including leaflet plication, percutaneous annuloplasty and valve implantation in either the tricuspid position (orthotopic implantation) or in a different position such as the vena cava (heterotopic implantation). These techniques, with promising outcomes, are seen as an interesting alternative to open-heart surgery given the much lower periprocedural risk.

show abstract

“…51 Unfortunately, there is a lack of systematic reviews comparing the different coaptation devices for TV repair. There is a recent review on coaptation devices 52 which discussed the limited literature on the outcomes from each of these devices. This showed the first comparative study 53 between the Mitraclip and Pascal techniques, concluding similar results between both.…”

Section: Interventions On the Leafletmentioning

confidence: 99%

Tricuspid valve diseases: Interventions on the forgotten heart valve

Yoganathan

Khan

et al. 2020

J Card Surg

View full text Add to dashboard Cite

Over the past few decades, the tricuspid valve (TV) interventions have been relatively lower compared to other cardiac valvular disease in terms of pathophysiology and management, especially regarding surgical intervention and therapy. However, recent crucial advances in assessment and management of the TV disease have resulted in a renewed interest in the "forgotten valve." The medical treatment aims to cure the underlying disease and address the presentation of the right heart failure. Surgical interventions have proven to yield good outcomes for those for whom surgery is indicated. For those who are not suitable for surgery, transcatheter surgery may prove to be a suitable replacement. Best practice with regard to surgical techniques is still in question due to limited data. This has been slowing the introduction of transcatheter interventions into common practical guidelines. The aim of this literature review is to discuss new insights on the pathophysiology, diagnosis, and interventions of TV disease, highlighting the surgical management and emerging transcatheter therapies. In addition, this review will provide an overview of the current state of the literature surrounding TV interventions and providing suggestions for future directives.

show abstract

Transcatheter Tricuspid Valve Intervention: Coaptation Devices

Cited by 31 publications

References 36 publications

Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program

Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program

Percutaneous Treatment of Tricuspid Regurgitation

Tricuspid valve diseases: Interventions on the forgotten heart valve

Contact Info

Product

Resources

About